BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting

Treatment of relapsed and/or refractory multiple myeloma (RRMM) utilizing the novel therapeutic target of the B-cell maturation antigen (BCMA) has demonstrated incredible results, leading to regulatory approval of BCMA-targeted chimeric antigen receptor (CAR)-T cell therapies in RRMM. With now two approved BCMA-targeted CAR-T cell therapies, investigators globally are working to build off and improve upon BCMA-targeted therapies. We discuss long-term data from the pivotal study that led to CAR-T approval, a phase 3 trial supporting their use in earlier lines, and novel manufacturing platforms to decrease vein-to-vein time. We highlight five key abstracts from the 2023 ASCO Annual Meeting that showcase these exciting updates in BCMA-directed CAR-T cell therapies in RRMM.

Automated summary

The use of BCMA as a therapeutic target has shown remarkable results in the treatment of RRMM, leading to the approval of BCMA-targeted CAR-T cell therapies. Researchers are now focusing on building upon and improving these therapies. This article discusses long-term data, a phase 3 trial supporting their use in earlier lines, and new manufacturing platforms to decrease treatment time. Additionally, it highlights five key abstracts from the 2023 ASCO Annual Meeting showcasing exciting updates in BCMA-directed CAR-T cell therapies in RRMM.